Eli Lilly Canada Inc.

12 articles with Eli Lilly Canada Inc.

• EMGALITY™ (galcanezumab) now available in Canada for preventive treatment of migraine

  10/2/2019

  New anti-CGRP treatment for the prevention of migraine in adults with at least 4 migraine days per month

• VERZENIO (abemaciclib) Available in Canada for Metastatic Breast Cancer

  8/8/2019

  Eli Lilly Canada Inc. (Lilly Canada) is pleased to announce the availability of VERZENIO™ (abemaciclib). VERZENIO is indicated for the treatment of estrogen and/or progesterone hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) metastatic breast cancer (

• With availability of Olumiant (baricitinib), Lilly brings new oral treatment option for Canadians living with rheumatoid arthritis

  11/1/2018

  "You would never know by looking at me," says Angela Vance, a Lilly employee, "that I have rheumatoid arthritis (RA)."

• Eli Lilly Canada and Women in Biz Network Partner to Shift Perceptions of Rheumatoid Arthritis in the Workplace

  10/12/2018

  A series of local events and career progression resources to support women living and working with a chronic disease

• Health Canada Approves Taltz (ixekizumab) for Treatment of Active Psoriatic Arthritis

  6/20/2018

  The approval of Taltz is based on the Phase 3 clinical trials that demonstrated efficacy on both joints and skin symptomsi

• Convenient prefilled insulin pen with flexible half-unit dosing approved and available in Canada

  5/3/2018

  Eli Lilly Canada Inc. (Lilly) is proud to announce that Humalog® [insulin lispro injection 100 units/mL] Junior KwikPen® is approved by Health Canada and now available to Canadians with diabetes.

• Eli Lilly Canada Inc. Release: Health Canada's Approval Of Taltz (Ixekizumab) Brings Targeted Therapy To Canadians Living With Moderate-To-Severe Plaque Psoriasis

  6/21/2016

• Boehringer Ingelheim And Eli Lilly Canada Inc. Release: Health Canada Approves JARDIANCE (empagliflozin) Tablets For Adults With Type 2 Diabetes

  11/30/2015

• Health Canada Approves Eli Lilly Canada Inc.'s Cymbalta for Knee Pain

  11/8/2012

• Boehringer Ingelheim Corporation and Eli Lilly Canada Inc. Present New linagliptin Data at American Diabetes Association's 72nd Scientific Sessions®

  6/11/2012

• FDA Delays Approval of Amylin Pharmaceuticals, Inc., Eli Lilly Canada Inc. (JOBS) Diabetes Drug; FDA Requests Finalization of Product Labeling

  3/15/2010

• Eli Lilly Turns To Japan

  3/25/2005